Amorfix and Biogen Partner to Develop ALS Therapy

Amorfix Life Sciences Ltd. announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix’s lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.

Click here to read more.

Share this: